Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer
Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable
FDA Approves Gleevec For First Line Rx Of CML
Fragmin Cuts Risk Of VE By 50 Percent In Study
Sirolimus-Containing Therapy Reduces GVHD, Study Finds
Avastin Regimen Bested Chemo Alone In Early Disease
Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca
Study Confirms Cancer Risk Increase Due To Combined HRT
Pill Associated With Cancer In BRCA1 Mutation Carriers
National Cancer Institute Lists Approved Clinical Trials
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
